公开(公告)号：WO2018067331A1

公开(公告)日：2018-04-12

申请号：PCT/US2017/053113

申请日：2017-09-22

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： HABER, Lauric ,  SMITH, Eric ,  KELLY, Marcus ,  KIRSHNER, Jessica R. ,  COETZEE, Sandra ,  CRAWFORD, Alison ,  NITTOLI, Thomas ,  LIU, Yashu

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44 ,  C07K16/46

Abstract: The present disclosure provides anti mucin 16 antibodies : bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. human IgG antibodies that bind to human andMUC16 (monospecific antibodies).anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo The antibodies are useful for the treatment of various cancers, including ovarian cancer.

Abstract translation: 本公开内容提供抗粘蛋白16抗体：双特异性抗体（bsAb），其在表达MUC16的肿瘤存在下结合MUC16和CD3并经由CD3复合物激活T细胞。 与人结合的人IgG抗体和MUC16（单特异性抗体）。抑制体内肿瘤生长的抗-MUC16抗体药物缀合物该抗体可用于治疗各种癌症，包括卵巢癌。

公开(公告)号：WO2015138460A1

公开(公告)日：2015-09-17

申请号：PCT/US2015/019722

申请日：2015-03-10

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： KIRSHNER, Jessica R. ,  MACDONALD, Douglas ,  THURSTON, Gavin ,  MARTIN, Joel H. ,  DELFINO, Frank ,  NITTOLI, Thomas ,  KELLY, Marcus

IPC: C07K16/28 ,  A61K47/48 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3069 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present disclosure provides antibodies that bind to the class III variant of EGFR (EGFRvlll) and methods of using the same. According to certain embodiments, the antibodies of the disclosure bind human EGFRvlll with high affinity. The antibodies of the disclosure may be fully human antibodies. The disclosure includes anti-EGFRvlll antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the disclosure are useful for the treatment of various cancers.

Abstract translation: 本公开提供结合EGFR（EGFRv111）的III类变体的抗体及其使用方法。 根据某些实施方案，本公开的抗体以高亲和力结合人EGFRv11I。 本公开的抗体可以是完全人抗体。 本公开内容包括与细胞毒素剂，放射性核素或对细胞生长或增殖有害的其它部分缀合的抗EGFRv11I抗体。 本公开的抗体可用于治疗各种癌症。